CDC-9 Inactivated Rotavirus Vaccine (IRV) Microneedle Patch (MNP) in Healthy Adults

NCT06962904 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2026-03-05

No results posted yet for this study

Summary

This is a study of CDC-9 inactivated rotavirus vaccine (IRV) microneedle patch (MNP) for intradermal administration in healthy adults aged 18 to 45 years at two dose levels in a 3-dose series. The purpose is to determine if it is safe and if the recipient's immune system responds to the vaccine.

Conditions

  • Rotavirus Infections

Interventions

BIOLOGICAL

3.75 µg Dose of CDC-9 Inactivated Rotavirus Vaccine (IRV)

CDC-9 IRV dissolving MNP for intradermal administration is comprised of a single human rotavirus strain for protection against rotavirus infection

BIOLOGICAL

7.5 µg Dose of CDC-9 Inactivated Rotavirus Vaccine (IRV)

CDC-9 IRV dissolving MNP for intradermal administration is comprised of a single human rotavirus strain for protection against rotavirus infection

OTHER

Placebo

Placebo MNP (containing sucrose, sorbitol, maltodextrin, methylcellulose, HEPES, sodium chloride, and calcium chloride) administered intradermally

Sponsors & Collaborators

Principal Investigators

  • Christina Rostad, MD · Emory Children's Center - Vaccine Research Clinic (ECC-VRC)

  • Lauren Nolan, PA-C · Emory Children's Center - Vaccine Research Clinic (ECC-VRC)

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-07-07
Primary Completion
2026-10-06
Completion
2026-10-06
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06962904 on ClinicalTrials.gov